The formulations showed an enhanced binding to prostate cancer cells (PSMA positive) along with the reduction in tumor size in prostate epithelial cells (LNCaP) as compared to non-targeted liposomes [120]. This evidence concerns the gene FOLH1 and Familial prostate cancer.